Today, we announced the submission of a New Drug Application (NDA) to the FDA for our investigational #RNAi medicine for treatment of familial chylomicronemia syndrome (#FCS). We plan to submit applications for approval to additional regulatory authorities in 2025. Learn more:?https://bit.ly/40OlfuR
关于我们
At Arrowhead Pharmaceuticals we are breaking the mold of medicine. We are pushing the boundaries of therapeutic development and revolutionizing how we care for hard-to-treat illnesses. As a company we harness collaboration and innovation to rapidly advance drugs from discovery to the clinic. All applicants: Please be aware of employment scams using Arrowhead’s name and the names of Arrowhead’s employees. All job related Arrowhead communication should come from the domain @arrowheadpharma.com.
- 网站
-
https://www.arrowheadpharma.com
Arrowhead Pharmaceuticals的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Pasadena,California
- 类型
- 上市公司
- 领域
- Biotech、Drug Development、Pharmaceuticals和RNAi
地点
Arrowhead Pharmaceuticals员工
动态
-
We’re here at the American Heart Association’s Scientific Sessions in Chicago. Find us at booth 1717 and let’s reimagine what’s possible for people with extremely high triglycerides. #AHA24 LowerTriglycerides.com
-
This #PancreasAwarenessMonth, we’re committed to advancing therapies for pancreatitis and other serious conditions. We’re advancing our #RNAi mechanism to potentially prevent the risk of developing acute pancreatitis. Thank you to The National Pancreas Foundation and Mission: Cure for making a difference in the lives of those affected by pancreas disease. Learn more: https://bit.ly/3Z5FkLV #ColorItPurple #PancreasAwareness #PancreaticHealth
-
Join us at the American Heart Association Scientific Sessions on November 16 & 18 for two upcoming presentations! We will be highlighting the potential of our #RNAi platform's ability to lower triglyceride levels in patients. Learn more: https://bit.ly/3u4qXua #AHA24
-
Arrowhead Pharmaceuticals was honored to be in Vienna, Austria, this weekend with the FH Europe Foundation, Action FCS and the community, connecting and discussing ways to improve awareness for FCS. Together, we’re working to support and empower patients on their journey to better health. #FHEF2024 #TogetherEngagedForChange #ForFCS
-
Join us November 26th at 4:30 p.m. ET for a live webcast as we discuss our financial results for the 2024 fiscal year. Find details on how to join the call or access the recording here: https://bit.ly/4fwtbF9
-
We have an exciting month ahead! We’re presenting at multiple investor, medical, and scientific conferences in November and sharing advancements across our pipeline of investigational #RNAi medicines. Check out the details here: https://bit.ly/3YOkKQ2
-
On this #FCSawareness Day, we’re imagining a different tomorrow for people with extremely high triglycerides despite standard of care. Learn more at lowertriglycerides.com #ForFCS #FightFCS
-
Today is #FCSAwareness Day, let’s raise awareness, drive research, and support those affected by Familial Chylomicronemia Syndrome (FCS). Arrowhead employees across the country are coming together with the global FCS community to raise awareness for patients, caregivers, and those dedicated to improving the lives of those impacted by this ultra rare condition. We are grateful to have special guests in our offices this week to kick off awareness activities by sharing their experiences living with FCS. At Arrowhead, everything we do is aimed at making someone’s life better. Together, we can make the invisible visible #ForFCS. Learn more: https://lnkd.in/e4W9564s Thank you to The FCS Foundation, Action FCS, FH Europe Foundation, and The National Pancreas Foundation for all you do to support the FCS community.
-
We're presenting at the American Heart Association (#AHA2024) Scientific Sessions in Chicago, IL! We're excited to share the latest advancements in our #RNAi technology and connect with leaders in lipidology and cardiometabolic disease. Learn more here: https://bit.ly/4eXdciW